Back

Proprotein convertase subtilisin/kexin type 9 (PCSK9) plasma levels are associated with the metabolic syndrome in patients with stable coronary artery disease

3 September 2019 (14:00 - 18:00)
Organised by:
Congress Presentation Part of: Poster Session 7 - Lipids Lipids ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Chiara Caselli

CNR – National Research Council, Pisa (Italy)

14 More presentations in this session

Presentation thumbnail
Doctor C. Rodriguez (The Bronx, US)
Abstract
Presentation thumbnail
Professor G. Schwartz (Aurora, US)
Abstract
Presentation thumbnail
Professor M. Banach (Lodz, PL)
Abstract Slides
Presentation thumbnail
Professor M. Banach (Lodz, PL)
Abstract Slides
Presentation thumbnail
Doctor M. Santos (Funchal, PT)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 7 - Lipids

The Event

Event poster

ESC Congress 2019

3 September 2019 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of proprotein covertase subtilisin/kexin type 9 inhibitors among patients with acute coronary syndrome: a meta-analysis of randomized controlled trials
27 August 2022
thumbnail
Congress Presentation
The Relationship between updated Systemic Coronary Risk Estimation (SCORE 2) and markers of subclinical atherosclerosis and target organ damage in asymptomatic population with metabolic syndrome
25 April 2024
thumbnail
Congress Presentation
Remnant cholesterol and its role in patients with coronary atherosclerosis evaluated by coronary CT
13 December 2025
thumbnail
Congress Presentation
Prevalence and influence of cardiovascular kidney metabolic syndrome on outcomes after transcatheter aortic valve implantation
31 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources